Poor aesthetics measured by patient (after restoration) · Patients receiving immediate single implants in fresh extraction sockets (maxillary anterior/premolar sites)
Bio-Oss (anorganic bovine bone) led to lower poor aesthetics measured by patient (after restoration) compared with bio-Oss + resorbable barrier; GRADE not reported.
1 finding from 1 review
Augmentation (prosthesis/implant) failure · Patients receiving immediate single implants in fresh extraction sockets (maxillary anterior/premolar sites)
Bio-Oss (anorganic bovine bone) led to lower augmentation (prosthesis/implant) failure compared with bio-Oss + resorbable barrier; GRADE not reported.
1 finding from 1 review
Poor aesthetics measured by dentist (3 years) · Patients receiving immediate single implants in fresh extraction sockets (maxillary anterior/premolar sites)
Bio-Oss (anorganic bovine bone) led to lower poor aesthetics measured by dentist (3 years) compared with bio-Oss + resorbable barrier; GRADE not reported.
1 finding from 1 review
After 3 years of loading, the operator judged aesthetics to be poor in 2/7 patients of the Bio-Oss group and in 2/5 of the Bio-Oss plus barrier group; no statistically significant difference.
1 study · 20 participants
GRADE not reported
Death (any cause) ( · heart failure with chronic kidney disease
It is very uncertain whether CHRONIC: Aldosterone antagonists changes death (any cause) ( compared with placebo (very low certainty).
1 finding from 1 review
Cardiovascular mortality · heart failure with chronic kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospitalisation (any cause) · heart failure with chronic kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Heart failure hospitalisation (RR) · heart failure with chronic kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Worsening heart failure · heart failure with chronic kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Worsening kidney function · heart failure with chronic kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypotension · heart failure with chronic kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hyperkalaemia · heart failure with chronic kidney disease
CHRONIC: Aldosterone antagonists may leads to higher hyperkalaemia compared with placebo (low certainty).
1 finding from 1 review
Quality of life · heart failure with chronic kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Efficacy and stability of fixation (bite force) · Adults with isolated mandibular fractures in the interforaminal region
1 finding from 1 review
Nausea · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in specific side effect ‐ nausea compared with levonorgestrel 1.5 mg (low certainty).
1 finding from 1 review
Vomiting · women seeking emergency contraception
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific side effects ‐ spotting/bleeding after treatment · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) may leads to lower specific side effect ‐ spotting/bleeding after treatment compared with levonorgestrel 1.5 mg (low certainty).
1 finding from 1 review
Menses ‐ early · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in menses ‐ early compared with levonorgestrel 1.5 mg (low certainty).
1 finding from 1 review
Menses ‐ delay · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) probably leads to higher menses ‐ delay compared with levonorgestrel 1.5 mg (moderate certainty).
1 finding from 1 review
Observed number of pregnancies (all women) · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) probably leads to lower observed number of pregnancies (all women) compared with levonorgestrel 1.5 mg (moderate certainty).
1 finding from 1 review
Side effects · women seeking emergency contraception
Mid‐dose mifepristone (25 mg‐50 mg) may leads to lower any side effect compared with levonorgestrel 1.5 mg (low certainty).
1 finding from 1 review